American Century Companies Inc. Purchases 23,864 Shares of argenex SE $ARGX

American Century Companies Inc. grew its holdings in shares of argenex SE (NASDAQ:ARGX) by 11.6% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 229,770 shares of the company’s stock after buying an additional 23,864 shares during the quarter. American Century Companies Inc. owned 0.37% of argenex worth $169,474,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of ARGX. Ninepoint Partners LP purchased a new stake in shares of argenex during the third quarter valued at $148,000. Handelsbanken Fonder AB boosted its position in argenex by 3.4% in the 3rd quarter. Handelsbanken Fonder AB now owns 41,105 shares of the company’s stock valued at $30,317,000 after buying an additional 1,352 shares during the period. Choreo LLC grew its stake in argenex by 11.3% in the 3rd quarter. Choreo LLC now owns 601 shares of the company’s stock worth $443,000 after acquiring an additional 61 shares in the last quarter. West Family Investments Inc. increased its position in shares of argenex by 5.6% during the third quarter. West Family Investments Inc. now owns 549 shares of the company’s stock worth $405,000 after acquiring an additional 29 shares during the period. Finally, AlphaCore Capital LLC purchased a new position in shares of argenex during the third quarter worth approximately $241,000. 60.32% of the stock is owned by institutional investors.

argenex Stock Down 0.6%

argenex stock opened at $766.92 on Monday. The stock has a 50-day moving average price of $826.36 and a 200 day moving average price of $813.13. The company has a market capitalization of $47.46 billion, a price-to-earnings ratio of 39.29, a price-to-earnings-growth ratio of 1.16 and a beta of 0.38. argenex SE has a 52 week low of $510.05 and a 52 week high of $934.62.

argenex (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, February 26th. The company reported $8.02 EPS for the quarter, beating the consensus estimate of $6.05 by $1.97. The business had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.30 billion. argenex had a net margin of 30.42% and a return on equity of 38.51%. Research analysts anticipate that argenex SE will post 3.13 EPS for the current fiscal year.

Key argenex News

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Positive Phase‑3 topline results for VYVGART in ocular myasthenia gravis (ADAPT OCULUS); study met its primary endpoint and argenx plans a supplemental BLA submission to expand the label into oMG, which materially expands commercial opportunity. argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial
• Positive Sentiment: Strong quarterly and full‑year commercial performance: $1.3B in Q4 product net sales and $4.2B for FY2025 (≈90% YoY growth), reinforcing revenue momentum and the company’s commercialization traction. argenx Reports Full Year 2025 Financial Results
• Positive Sentiment: Q4 beat on the numbers: $8.02 EPS vs. $6.05 consensus and $1.32B revenue vs. $1.30B consensus, with healthy margins and ROE — data that supports higher earnings expectations. MarketBeat Q4 Earnings Summary
• Positive Sentiment: Certain sell‑side firms raised targets after the results (Citizens JMP and HC Wainwright among them), signaling continued analyst conviction in upside from commercialization and label expansion. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Other major firms trimmed price targets (Wells Fargo, Guggenheim, RBC) but generally maintained positive ratings (overweight/outperform/buy). These adjustments temper upside expectations but keep buy convictions intact. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Reports flag a “large increase” in short interest for February, but the published short‑interest numbers appear inconsistent/erroneous (zeros/NaN). As reported data is unreliable, the market impact is unclear.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Morgan Stanley lifted their price objective on argenex from $1,070.00 to $1,110.00 and gave the company an “overweight” rating in a report on Thursday, December 4th. Royal Bank Of Canada reduced their price target on shares of argenex from $925.00 to $890.00 and set an “outperform” rating for the company in a report on Friday. Truist Financial increased their price objective on shares of argenex from $950.00 to $1,030.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a research note on Wednesday, January 21st. Finally, DZ Bank upgraded argenex to a “strong-buy” rating in a report on Friday, December 19th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, argenex has an average rating of “Moderate Buy” and an average price target of $999.22.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.